IP Library Granted Patent US 8,927,527
Granted Patent B2
US 8,927,527 · App. 13/655,618 · Granted Jan 6, 2015

Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,927,527
App. No.
13/655,618
Granted
Jan 6, 2015
Kind
B2
Abstract

The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.

Claims (40)

1. A compound of structural Formula (I):

or a salt thereof, wherein:

R 1 , R 2 , R 3 and R 4 are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, heteroarylalkyl, substituted heteroarylalkyl, halogen, hydroxy, or nitro;

R 5 and R 6 each represent independently for each occurrence hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, heteroarylalkyl, substituted heteroarylalkyl, halogen, hydroxy, or nitro;

R 7 is

a substituted acyl selected from the group consisting of substituted —C(O)-cycloalkyl, substituted —C(O)-aryl, substituted —C(O)-arylalkyl, substituted —C(O)-heteroaryl, substituted —C(O)-heteroarylalkyl, and an —C(O)-alkyl substituted by one or more substituents independently selected from the group consisting of halogen, —OR 60 , —SR 60 , —CF 3 , —OS(O) 2 R 60 , —OP(O)(OR 60 )(OR 61 ), and —OP(O)(OH) 2 ;

R 60 represents independently for each occurrence alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

R 61 represents independently for each occurrence hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

o is 0, 1, 2, 3 or 4; and

provided that at least two of R 1 , R 2 , R 3 , R 4 , —R 5 and R 6 are nitro.

2. The compound of claim 1 , wherein two of R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are nitro.

3. The compound of claim 1 , wherein R 1 , R 2 , and R 3 are each independently hydrogen, alkyl, aryl, or nitro; and R 5 and R 6 each represent independently for each occurrence hydrogen, alkyl, aryl, or nitro.

4. The compound of claim 2 , wherein R 1 , R 2 , and R 3 are each independently hydrogen, alkyl, aryl, or nitro; and R 5 and R 6 each represent independently for each occurrence hydrogen, alkyl, aryl, or nitro.

5. The compound of claim 1 , wherein R 3 is nitro; and R 1 , R 2 , R 4 , R 5 , and R 6 each represent independently for each occurrence hydrogen, alkyl, aryl, or nitro.

6. The compound of claim 2 , wherein R 3 is nitro; and R 1 , R 2 , R 4 , R 5 , and R 6 each represent independently for each occurrence hydrogen, alkyl, aryl, or nitro.

7. The compound of claim 1 , wherein R 3 and R 4 are nitro; and R 1 , R 2 , R 5 , and R 6 each represent independently for each occurrence hydrogen, alkyl, or aryl.

8. The compound of claim 2 , wherein R 3 and R 4 are nitro; and R 1 , R 2 , R 5 , and R 6 each represent independently for each occurrence hydrogen or alkyl.

9. The compound of claim 1 , wherein R 7 is —C(O)-cycloalkyl, —C(O)-arylalkyl, —C(O)-heteroarylalkyl, or —C(O)-alkyl, each of which is substituted by one or more substituents independently selected from the group consisting of halogen, —OR 60 , and —OS(O) 2 R 60 .

10. The compound of claim 4 , wherein R 7 is —C(O)-cycloalkyl, —C(O)-arylalkyl, —C(O)-heteroarylalkyl, or —C(O)-alkyl, each of which is substituted by one or more substituents independently selected from the group consisting of halogen, —OR 60 , and —OS(O) 2 R 60 .

11. The compound of claim 1 , wherein R 7 is —C(O)-arylalkyl or —C(O)-alkyl, each of which is substituted by one or more substituents independently selected from the group consisting of halogen, —OR 60 , and —OS(O) 2 R 60 ; and R 60 is alkyl, substituted alkyl, aryl, or substituted aryl.

12. The compound of claim 4 , wherein R 7 is —C(O)-arylalkyl or —C(O)-alkyl, each of which is substituted by one or more substituents independently selected from the group consisting of halogen, —OR 60 , and —OS(O) 2 R 60 ; and R 60 is alkyl, substituted alkyl, aryl, or substituted aryl.

13. The compound of claim 1 , wherein R 7 is —C(O)-alkyl substituted with a halogen.

14. The compound of claim 4 , wherein R 7 is —C(O)-alkyl substituted with a halogen.

15. The compound of claim 1 , wherein R 7 is —C(O)—CH 3 substituted with a halogen.

16. The compound of claim 4 , wherein R 7 is —C(O)—CH 3 substituted with a halogen.

17. The compound of claim 8 , wherein R 7 is —C(O)—CH 3 substituted with a halogen.

18. The compound of claim 1 , wherein variable o is 2 or 3.

19. The compound of claim 4 , wherein variable o is 2 or 3.

20. The compound of claim 17 , wherein variable o is 2 or 3.

21. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable vehicle.

22. A compound of structural Formula (I):

or a salt thereof, wherein:

R 1 , R 2 , R 3 and R 4 are independently hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, heteroarylalkyl, substituted heteroarylalkyl, halogen, hydroxy, or nitro;

R 5 and R 6 each represent independently for each occurrence hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroalkyl, substituted heteroalkyl, heteroarylalkyl, substituted heteroarylalkyl, halogen, hydroxy, or nitro;

R 7 is —C(O)-alkyl substituted by one or more substituents independently selected from the group consisting of halogen, —OR 60 , —SR 60 , —CF 3 , —OS(O) 2 R 60 , —OP(O)(OR 60 )(OR 61 ), and —OP(O)(OH) 2 ;

R 60 represents independently for each occurrence alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

R 61 represents independently for each occurrence hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

o is 0, 1, 2, 3 or 4; and

provided that at least one of R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are nitro.

23. A pharmaceutical composition comprising a compound of claim 22 and a pharmaceutically acceptable vehicle.

Assignments (12)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2021
From: NORTHROP GRUMMAN INNOVATION SYSTEMS LLC
To: NORTHROP GRUMMAN SYSTEMS CORPORATION
Reel/Frame 055256/0892 →
CHANGE OF NAME Recorded Feb 4, 2021
From: NORTHROP GRUMMAN INNOVATION SYSTEMS, INC.
To: NORTHROP GRUMMAN INNOVATION SYSTEMS LLC
Reel/Frame 055223/0425 →
CHANGE OF NAME Recorded Nov 1, 2018
From: ORBITAL ATK, INC.
To: NORTHROP GRUMMAN INNOVATION SYSTEMS, INC.
Reel/Frame 047400/0381 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Jun 6, 2018
From: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
To: ORBITAL ATK, INC.
Reel/Frame 046477/0874 →
RELEASE OF SECURITY INTEREST Recorded Oct 8, 2015
From: BANK OF AMERICA, N.A.
To: ALLIANT TECHSYSTEMS INC.; FEDERAL CARTRIDGE CO.; EAGLE INDUSTRIES UNLIMITED, INC.; AMMUNITION ACCESSORIES, INC.; ORBITAL ATK, INC. (F/K/A ALLIANT TECHSYSTEMS INC.)
Reel/Frame 036816/0624 →
SECURITY AGREEMENT Recorded Sep 30, 2015
From: ORBITAL ATK, INC.; ORBITAL SCIENCES CORPORATION
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 036732/0170 →
CHANGE OF NAME Recorded May 22, 2015
From: ALLIANT TECHSYSTEMS INC.
To: ORBITAL ATK, INC.
Reel/Frame 035753/0373 →
CHANGE OF NAME Recorded Nov 24, 2014
From: RADIORX, INC.
To: EPICENTRX, INC.
Reel/Frame 034432/0607 →
SECURITY AGREEMENT Recorded Nov 26, 2013
From: ALLIANT TECHSYSTEMS INC.; CALIBER COMPANY; EAGLE INDUSTRIES UNLIMITED, INC.; FEDERAL CARTRIDGE COMPANY; SAVAGE ARMS, INC.; SAVAGE RANGE SYSTEMS, INC.; SAVAGE SPORTS CORPORATION
To: BANK OF AMERICA, N.A.
Reel/Frame 031731/0281 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2013
From: OEHLER, LYNN M.; KNOX, SUSAN; NING, SHOUCHENG
To: RADIORX, INC., C/O INTERWEST VENTURE PARTNERS
Reel/Frame 031101/0607 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2013
From: CANNIZZO, LOUIS; WARNER, KIRSTIN; WARDLE, ROBERT; VELARDE, STEPHEN
To: ALLIANT TECHSYSTEMS INC.
Reel/Frame 031093/0971 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT SUPPLEMENT Recorded Jan 31, 2013
From: ALLIANT TECHSYSTEMS INC.
To: BANK OF AMERICA, N.A.
Reel/Frame 029732/0140 →